JP2023541443A - ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。 - Google Patents

ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。 Download PDF

Info

Publication number
JP2023541443A
JP2023541443A JP2023516689A JP2023516689A JP2023541443A JP 2023541443 A JP2023541443 A JP 2023541443A JP 2023516689 A JP2023516689 A JP 2023516689A JP 2023516689 A JP2023516689 A JP 2023516689A JP 2023541443 A JP2023541443 A JP 2023541443A
Authority
JP
Japan
Prior art keywords
gjb2
cells
nucleic acid
isolated nucleic
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541443A5 (https=
Inventor
コーリー，デイビッド，ピー．
ブース，ケビン，ティー．
ピータース，コール，ダブリュー．，ディー．
イワンチェンコ，マリナ，ヴイ．
グリーンバーグ，マイケル，イー．
フルヴァティン，シニシャ
ナギ－，マーク，オーレル
グリフィス，エリック，シー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2023541443A publication Critical patent/JP2023541443A/ja
Publication of JP2023541443A5 publication Critical patent/JP2023541443A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023516689A 2020-09-14 2021-09-14 ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。 Pending JP2023541443A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063078233P 2020-09-14 2020-09-14
US63/078,233 2020-09-14
US202163161619P 2021-03-16 2021-03-16
US63/161,619 2021-03-16
PCT/US2021/050205 WO2022056444A1 (en) 2020-09-14 2021-09-14 Recombinant adeno associated virus (raav) encoding gjb2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2023541443A true JP2023541443A (ja) 2023-10-02
JP2023541443A5 JP2023541443A5 (https=) 2024-09-26

Family

ID=80631939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516689A Pending JP2023541443A (ja) 2020-09-14 2021-09-14 ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。

Country Status (10)

Country Link
EP (1) EP4211151A4 (https=)
JP (1) JP2023541443A (https=)
KR (1) KR20230069157A (https=)
AU (1) AU2021339843A1 (https=)
BR (1) BR112023004605A2 (https=)
CA (1) CA3191533A1 (https=)
IL (1) IL301057A (https=)
MX (1) MX2023002978A (https=)
TW (1) TW202227476A (https=)
WO (1) WO2022056444A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021067448A1 (en) * 2019-09-30 2021-04-08 Applied Genetic Technologies Corporation Adeno-associated virus (aav) systems for treatment of genetic hearing loss
WO2024011224A2 (en) * 2022-07-08 2024-01-11 The Trustees Of Columbia University In The City Of New York Regulatory element for cell type specific expression of genes in spinal motor neurons
WO2024218192A1 (en) * 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
EP4713463A1 (en) * 2023-05-18 2026-03-25 Decibel Therapeutics, Inc. Compositions and methods for treating gjb2-related hearing loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308458A1 (en) * 2001-10-30 2003-05-07 GenOdyssee New polynucleotides and polypeptides of the CX26 gene
WO2019200016A1 (en) * 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
WO2021231808A2 (en) * 2020-05-13 2021-11-18 Akouos, Inc. Compositions and methods for treating gjb2-associated hearing loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005019174D1 (de) * 2004-06-17 2010-03-18 Epigenomics Ag Zusammensetzungen und verfahren zur verhinderung des mitschleppens einer kontamination in nukleinsäure-amplifikationsreaktionen
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
WO2020077295A1 (en) * 2018-10-11 2020-04-16 Decibel Therapeutics, Inc. Aav1 vectors and uses thereof for treatment of otic indications
EP4063510A1 (en) * 2018-11-07 2022-09-28 Akouos, Inc. Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
WO2021067448A1 (en) * 2019-09-30 2021-04-08 Applied Genetic Technologies Corporation Adeno-associated virus (aav) systems for treatment of genetic hearing loss
MX2023013394A (es) * 2021-05-13 2023-12-14 Akouos Inc Composiciones de suministro de terapia genica y metodos para tratar perdida auditiva.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308458A1 (en) * 2001-10-30 2003-05-07 GenOdyssee New polynucleotides and polypeptides of the CX26 gene
WO2019200016A1 (en) * 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
WO2021231808A2 (en) * 2020-05-13 2021-11-18 Akouos, Inc. Compositions and methods for treating gjb2-associated hearing loss

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1443, JPN6025044663, 1998, pages 169 - 181, ISSN: 0005721291 *
DATEBASE: GENBANK, ACCESSION: AL138688, DEFINITION: HUMAN DNA SEQUENCE FROM CLONE RP11-264J4 ON CHRO, JPN6025044664, 13 December 2012 (2012-12-13), ISSN: 0005721290 *

Also Published As

Publication number Publication date
CA3191533A1 (en) 2022-03-17
EP4211151A1 (en) 2023-07-19
MX2023002978A (es) 2023-06-01
KR20230069157A (ko) 2023-05-18
TW202227476A (zh) 2022-07-16
AU2021339843A1 (en) 2023-04-06
EP4211151A4 (en) 2025-03-26
IL301057A (en) 2023-05-01
BR112023004605A2 (pt) 2023-04-11
WO2022056444A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
JP7814430B2 (ja) 深部イントロン突然変異の遺伝子編集
US12054724B2 (en) AAV vectors encoding clarin-1 or GJB2 and uses thereof
JP2023541443A (ja) ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。
US12612645B2 (en) AAV vectors encoding mini-PCDH15 and uses thereof
US20240016955A1 (en) Dual-aav vector delivery of pcdh15 and uses thereof
CA3130515A1 (en) Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
JP2024109708A (ja) 非症候性感音性聴力喪失の治療方法
US20230089490A1 (en) Raav-mediated in vivo delivery of suppressor trnas
JP7671790B2 (ja) 眼疾患の遺伝子治療
US20230340038A1 (en) Recombinant adeno associated virus (raav) encoding gjb2 and uses thereof
US12129287B2 (en) Recombinant adeno associated virus encoding clarin-1 and uses thereof
WO2024069144A1 (en) Rna editing vector
CA3116391A1 (en) Recombinant adeno associated virus encoding clarin-1 and uses thereof
WO2025170984A1 (en) Cell-type-specific control of gene expression in auditory hair cells
TW202604549A (zh) 基因治療劑之剖析
HK40116478A (zh) 深内含子突变的基因编辑
Scalabrino Adeno associated viral gene therapy targeting on bipolar cells restores function in a mouse model of congenital stationary night blindness
HK1252469B (en) Gene editing of deep intronic mutations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240917

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20251002

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20251002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424